Metabolic changes linked to intravenous ketamine in hard-to-treat major depression

Using data from the Bio-K trial with N=xxx, metabolomic signatures of intravenous ketamine were characterized in adults with treatment-resistant depression.

• Ketamine is known as a rapid-acting antidepressant, but its exact mechanism of action is not fully understood.
• Pharmacometabolomics may help identify biological pathways related to ketamine's effects.
• Variability in response to ketamine treatment could be linked to individual metabolomic profiles.
• The study focuses on adults diagnosed with treatment-resistant depression.

Simplified